Gastric cancer is one of the most common cancers worldwide and is responsible for approximately 800,000 deaths annually [1]. It has third leading cause of cancer-associated mortality worldwide. Despite improvements in treatment modalities for gastric cancer, the prognosis for advanced cases following curative resection remains poor [2].

Preoperative circulating tumor cells (CTCs) are a prognostic indicator in gastric cancer and also valuable for predicting progression-free survival [3]. CTCs and circulating tumor DNA (ctDNA) serve as complementary liquid biopsy modalities in gastric cancer for disease monitoring, prognostication, and therapeutic decision-making. While ctDNA demonstrates higher sensitivity for detecting tumor-specific genetic alterations and minimal residual disease, CTCs provide valuable information regarding metastatic potential and tumor cell biology.

The study presents a significant theoretical advancement and identifies potential novel insights in gastric cancer findings: CTCs-positive status was significantly associated with aggressive clinicopathological features, including advanced tumor stage and metastasis. CTCs in gastric cancer are malignant cells that detach from the primary tumor and enter the bloodstream. These cells are considered important precursors of metastasis and play a significant role in cancer progression.

The detection of CTCs provides a non-invasive “liquid biopsy” approach that can be used for prognosis assessment, treatment monitoring, and evaluation of disease progression in patients with gastric cancer. Studies have shown that the presence of CTCs is associated with poorer survival outcomes and an unfavorable prognosis.

The study recommends integrating preoperative CTC testing into the clinical management of patients to improve risk stratification and guide personalized treatment strategies. We suggest that further prospective studies are warranted to validate the utility of optimizing the use of ctDNA. ctDNA has potential applications in gastric cancer. These will be very helpful for early gastric cancer screening and for detection of minimal residual disease [4]. ctDNA plays an important role in therapeutic monitoring following curative surgery, in the management of advanced disease, and in treatment decision-making. Compared with tissue-based next-generation DNA sequencing, ctDNA analysis provides a non-invasive and convenient approach for assessing the tumor genomic landscape [5]. In addition, can potentially overcome the challenges of tumor heterogeneity seen with tissue-based next-generation DNA sequencing. The combined analysis of CTCs and ctDNA aims to clarify the fundamental biological and clinical significance of their complementarity. In gastric cancer, CTCs provide comprehensive insights into tumor cell morphology, RNA and protein expression profiles, and can additionally be utilized for in vitro drug sensitivity assays and the establishment of patient-derived xenograft models, thereby offering significant value for functional studies. In contrast, ctDNA offers advantages in terms of broader genomic coverage and ease of detection. The integration of CTC and ctDNA analyses is not intended merely to improve detection rates, but rather to provide a multidimensional characterization of tumor biology by capturing complementary aspects of the disease, including genomic alterations and functional phenotypic features. Genotypically, both CTCs and ctDNA capture the high inter- and intra-tumoral heterogeneity of gastric cancer. ctDNA is genotype-focused with high-sensitivity mutation detection (e.g., HER2, KRAS) and thus useful for identifying targetable mutations.

The presence of malignant cells in the bloodstream has been recognized for many years. Tumor cells release DNA fragments into the circulation, known as ctDNA. These tumor-derived components can be detected in patients with gastric cancer through a blood-based test referred to as a liquid biopsy. In gastric cancer, CTCs and ctDNA serve as valuable non-invasive biomarkers for liquid biopsy applications [6]. CTCs are promising minimally invasive biomarkers for tumor biology and metastasis. These biomarkers help assess the genetic profile of tumors, provide insight into the mechanisms of cancer development, and identify actionable mutations that may be targeted with specific therapies. They may also be used for the screening and clinical management of patients with gastric cancer. ctDNA has been recognized as an important prognostic biomarker across all stages of gastric cancer. Furthermore, quantification of ctDNA levels is valuable for identifying mechanisms of resistance to ongoing therapy and for predicting treatment response and disease progression. Thus, they will aid in early diagnosis, detecting minimal residual disease post-surgery, and predicting treatment response mainly in cases of targeted therapies like HER2/ERBB2, HER2 overexpression or amplification, MET inhibitors, PDL1, and FRGFR2 overexpression [7]. They also help in monitoring drug resistance for assessing prognosis. The combined CTC/ctDNA analysis shows high accuracy for predicting metastasis risk.

Measuring ctDNA levels and methylation patterns can identify gastric cancer up to four years earlier than standard imaging. Advanced techniques like next-generation sequencing and digital PCR have improved the sensitivity and specificity of ctDNA detection [8]. It also helps in response monitoring of a patient. A > 90% decrease in ctDNA levels after chemotherapy or immunotherapy initiation indicates a positive prognosis.

Liquid biopsy offers several advantages over conventional tissue biopsy, particularly due to its minimally invasive nature and ability to provide dynamic, real-time information about tumor biology. Unlike traditional tissue sampling, liquid biopsy can be performed repeatedly through a simple blood draw, making it a safer and more convenient approach for patients. In addition, it enables the early detection of cancer, facilitates continuous monitoring of disease progression and treatment response, and assists in the identification of emerging therapeutic resistance. These features make liquid biopsy a promising tool for personalized cancer management, especially in patients with gastric cancer. A blood-based ctDNA analysis is a non-invasive, cost-effective method that would be helpful to anticipate gastric cancer detection before the advanced stage. In clinical practice, it would contribute to a considerable reduction in cancer-related mortalities.

Recently, Donaldson and Park’s study [9] showed that ctDNA in blood plasma has become a promising cancer biomarker. In patients with localized disease, qualitative and quantitative analysis of cell-free DNA (cfDNA) and ctDNA has the potential to provide valuable information regarding the risk of cancer recurrence and metastatic spread [10]. Preoperative positivity for CTCs is linked to more aggressive tumor characteristics, including greater depth of invasion (higher T-stage) and the presence of distant metastases. ctDNA has emerging clinical applications across the entire continuum of gastric cancer management. These applications include early cancer screening, preoperative assessment, postoperative surveillance, treatment response monitoring, early detection of recurrence, and management of advanced-stage disease. High levels of pre-surgical ctDNA are associated with higher-grade histology, advanced T-stage, and increased mortality risk.

ctDNA analysis provides a minimally invasive approach for real-time evaluation of tumor dynamics and molecular alterations, thereby supporting personalized treatment strategies and improving disease monitoring in patients with gastric cancer.

ctDNA analysis can identify genetic mutations, copy number variations, and methylation patterns (e.g., in genes like SOX17, RUNX3, and TFPI2) to track cancer progression, assess tumor heterogeneity, and predict response to targeted therapies [11].

The integrated and multi-modal approaches to improve detection by a combination of CTCs, ctDNA, protein markers, genomics, transcriptomics, proteomics, and AI-enhanced advanced imaging are coming up for precise diagnostic strategies in gastric cancers. Approaches such as combining ctDNA mutation analysis with protein tumor markers (e.g., CA-125, CEA [carcinoembryonic antigen]) enhance detection sensitivity for early-stage cancers. DNA methylation is a key epigenetic change in various cancers [12]. Epigenetic changes in gastric cancer often occur early in tumor development. It contributes to carcinogenesis by silencing tumor suppressor genes through hypermethylation and, in some cases, by activating oncogenes [13]. Studies indicate that ctDNA methylation profiles can detect gastric cancer early and distinguish it from benign lesions. Methylation-based ctDNA assays generally offer greater sensitivity for early detection of gastric cancer. Validated methylated loci, including RASSF1A, CDH1, and SALL3, are commonly hypermethylated in gastric cancer and demonstrate high specificity as diagnostic biomarkers.

A study by Li et al. [14] demonstrated that, despite the limited number of established therapeutic targets in gastric cancer, ctDNA analysis is valuable for detecting genomic alterations that may guide the selection of more personalized treatment strategies. Similarly, Lengyel et al. [15] highlighted the emerging role of liquid biopsy in gastric cancer, emphasizing that ctDNA has significant clinical utility in prognostic prediction, assessment of treatment response, early disease detection, identification of patients eligible for targeted therapies, and, more recently, selection of candidates for immunotherapy. Emerging evidence indicates that ctDNA monitoring aids in differentiating pseudoprogression from true disease progression during immune checkpoint inhibitor therapy in gastric cancer.

Recent studies in 2025 and 2026 have highlighted that detecting CTCs and ctDNA in peritoneal lavage fluid rather than just blood offers the highest accuracy (up to 85%) for predicting peritoneal metastasis. A recent study by Zhao et al. [16] provided innovative insights into gastric cancer and outlined future research directions through the application of single-cell RNA sequencing. This advanced transcriptomic approach enables high-resolution characterization of tumor heterogeneity, identification of distinct cellular subpopulations, and a deeper understanding of the tumor microenvironment, thereby offering new perspectives for precision oncology and the development of targeted therapeutic strategies. Rays et al. [17] observed that in metastatic gastric cancer, selecting patients for immunotherapy in second and subsequent lines remains challenging. In gastric cancer, emerging research is focusing on integrating ctDNA with additional biomarkers, such as circulating non-coding RNAs (including miRNAs, circRNAs, and lncRNAs) and DNA methylation patterns, to improve diagnostic accuracy and detection sensitivity [18, 19]. Preliminary results of PanSeer, a noninvasive blood test based on ctDNA methylation, demonstrate the detection of cancer in 95% of asymptomatic individuals who were later diagnosed with cancer [20]. Changes in ctDNA levels serve as a dynamic indicator of tumor burden during neoadjuvant chemotherapy or chemoimmunotherapy [21]. A rapid reduction or complete clearance of ctDNA following surgery or during neoadjuvant treatment is strongly associated with a favorable pathological complete response and improved long-term survival outcomes. In contrast, detection of ctDNA after surgery is linked to reduced recurrence-free survival. In advanced gastric cancer, ctDNA also plays an important role in monitoring response to targeted therapies [22].

ctDNA testing in gastric cancer faces challenges in clinical application, particularly regarding its low shedding in early-stage disease, which limits sensitivity. Another is related to the lack of standardization in pre-analytical and analytical methods, such as optimal timing for blood draws and utilization of specialized tubes to reduce pre-analytical variability. Clonal Hematopoiesis of Indeterminate Potential (CHIP) is an important age-related challenge in the application of cfDNA assays for cancer detection, especially in older individuals at risk for gastric cancer, which introduces false-positive variants [23].

Despite remarkable progress in surgical techniques, chemotherapy, and targeted therapies, the survival rates for patients diagnosed with advanced gastric cancer remain disappointingly low, so future research directions are appreciated.

In gastric cancer, ctDNA is emerging as a highly promising liquid biopsy biomarker for diagnosis, minimal residual disease detection, prognosis, treatment monitoring, and precision therapy selection. The ctDNA is often more abundant and stable in the blood than the rare and fragile CTCs. The ctDNA potentially has higher sensitivity in detection and real-time monitoring of tumor dynamics and treatment response. The integrated and multi-modal approaches to improve detection by a combination of ctDNA, CTCs, protein markers, genomics, transcriptomics, proteomics, and AI-enhanced advanced imaging are being developed for precise diagnostic strategies in gastric cancers. Future advances are focused on enhancing sensitivity in low-shedding tumors, integrating methylation profiling, and using ctDNA-guided adaptive therapy strategies to increase the intensity of patient care in gastric cancer.